Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray–Based Assessment of Outcome
C. Moeder(BC Cancer Agency), David L. Rimm(Yale University)
Cited by 109
Related Papers
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
|JAMA Oncology|2015|834
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
|Cancer Immunology Research|2014|391
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
|Modern Pathology|2016|166
Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study
|Laboratory Investigation|2018|138
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations
|Journal of Thoracic Oncology|2018|111